Pfizer's COVID-19 Vaccine Brings Gaps In Efficacy And Safety Data To US FDA Panel

 
• By Sue Sutter

Agency details a host of unknowns regarding the benefits and risks of the first COVID-19 vaccine to reach the advisory committee stage, including uncertainties about duration of protection, effectiveness against transmission and vaccine-enhanced disease.

Brokeen bridge with gap above city view
The FDA's external experts will decide whether or not to recommend a vaccine EUA despite large gaps in the efficacy and safety data. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers